1 results match your criteria: "Center for Inspection of JSMPA[Affiliation]"
Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis.
Adv Ther
March 2023
Center for Inspection of JSMPA, No. 8 Jiangdong Street, Nanjing, 210008, People's Republic of China.
Article Synopsis
- CMAB008 is a monoclonal antibody created to be similar to the existing drug infliximab (Remicade), and its pharmacokinetics were compared between healthy individuals and those with rheumatoid arthritis (RA).
- A population pharmacokinetic model was developed based on various studies, revealing a two-compartment model that accurately described the drug concentration in both groups, while noting certain factors like body weight and albumin levels influenced drug clearance.
- The findings confirmed that CMAB008 and Remicade have similar pharmacokinetic profiles, supporting the use of CMAB008 as a bioequivalent treatment option for RA.